6 No-Brainer Artificial Intelligence (AI) Stocks to Buy Hand Over Fist After Taiwan Semiconductor Manufacturing Earnings

A short, promotional video discusses recent developments affecting Taiwan Semiconductor Manufacturing and Nvidia alongside other AI-related stocks but provides no new financial metrics or guidance. The piece emphasizes that TSMC was not included in The Motley Fool Stock Advisor's current top-10 picks, cites historical outperformance of past recommendations (Netflix, Nvidia), notes after-market pricing as of Jan. 15, 2026, and discloses holdings and potential compensation ties for the author and The Motley Fool.

Analysis

Market structure: Nvidia (NVDA) is the primary beneficiary of the AI compute boom — software/IP-driven margin capture grows faster than foundry revenue, so expect NVDA to outgrow peers by 20–40% EPS CAGR over 12–24 months if model demand holds. TSMC (TSM) benefits from tight wafer capacity and EUV-dependent nodes but faces lagged revenue recognition and pricing pressure if Nvidia vertical integration accelerates; legacy fabs/IDMs (e.g., INTC) are the losers. Supply/demand: near-term wafer lead times and ASML tool delivery constraints keep pricing power with tier-1 foundries through 2026; risk of oversupply rises if capex expands >20% industry-wide in 2026–2027.

Risk assessment: Tail risks include stricter export controls or a Taiwan geopolitical shock (low-probability 5–15% but high-impact), a sudden AI demand slowdown (20–40% downturn in GPU orders), or major yield issues at advanced nodes. Time horizons split: days — momentum and volatility around earnings; weeks/months — guidance revisions and tool shipments; quarters/years — capex cycles and structural market-share shifts. Hidden dependencies: Nvidia’s moat depends on CUDA ecosystem and hyperscaler procurement concentration (top 5 customers >50% of revenue).

Trade implications: Favor concentrated NVDA exposure for asymmetric upside (6–12 month horizon) while hedging sector/capex risk with short semiconductor ETF exposure; size trades to 1–4% of portfolio per position and re-evaluate after earnings or policy news. Options: prefer calendar/vertical spreads to limit theta bleed; enter TSM on pullbacks >8% or via 12–18 month LEAPs to capture capex-led recovery. Catalysts to watch: NVDA earnings, TSM investor day, ASML deliveries, and US export-policy announcements over next 30–180 days.

Contrarian angles: Consensus may underprice TSM’s near-term pricing power and overprice NVDA near-term multiple expansion — a 10–20% NVDA pullback would be a buying opportunity but a >30% rally without capex discipline risks mean reversion. Historical parallel: 2016–18 GPU cycles show software-led winners captured disproportionate value while foundries earned cyclical profits; an industry-wide capex surge could flip winners to losers in 12–24 months. Unintended consequence: broad AI hype can trigger overbuild, creating a 18–30 month trough in utilization and compressing margins across semiconductors.

Key Decisions for Investors

• Establish a 2–3% long position in NVDA (direct shares) now, add up to +1% on confirmed pullback of 8–12%; target +30% in 6–12 months, hard stop/reevaluate at -15% intraday move on volume or after negative guidance.
• Buy NVDA 6–9 month call spread (debit) targeting delta ~0.30–0.40 calls to cap cost; allocate 1–2% of portfolio notional to this options sleeve to capture upside while limiting theta risk.
• On any TSM pullback >8% within 3 months, establish a 2% position via 12–18 month LEAP calls (10–20% OTM) or sell 12-month cash-secured puts 10% OTM to acquire at a favorable basis; target +25% in 12–24 months.
• Implement a pair hedge: go long NVDA equal-weight to a short position in SMH (VanEck Semiconductor ETF) sized so net sector beta ~0.3; purpose is to isolate company-specific upside vs semiconductor-cycle risk.
• Reduce cyclical semiconductor exposure outside tier-1 AI beneficiaries by 1–2% if industry capex guidance increases >20% y/y for 2026–2027, as oversupply risk would likely compress margins 15–30% within 12–24 months.